Mid Atlantic Retina

Running trials

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· 4D Molecular Therapeutics· Source

• Recruiting

  Study of ALK-001 on the Progression of Stargardt Disease

  NCT07419334· Phase 3· Alkeus Pharmaceuticals, Inc.· Source

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

  NCT07440225· Phase 2/3· EyeBiotech Ltd.· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

  NCT07425574· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· AbbVie· Source

• Recruiting

  A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

  NCT07144137· Complement Therapeutics· Source

• Recruiting

  A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

  NCT07215390· Phase 2· Apellis Pharmaceuticals, Inc.· Source

• Recruiting

  A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

  NCT06789445· Phase 1/2· BlueRock Therapeutics· Source

• Active, not recruiting

  4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT06864988· Phase 3· 4D Molecular Therapeutics· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

  NCT06491914· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

  NCT06373731· Phase 3· Stealth BioTherapeutics Inc.· Source

• Active, not recruiting

  A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

  NCT04850118· Phase 2/3· Beacon Therapeutics· Source

• Active, not recruiting

  Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

  NCT06018558· Phase 1/2· Ocugen· Source

• Active, not recruiting

  Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

  NCT06087458· Phase 1/2· Perceive Biotherapeutics, Inc.· Source

• Recruiting

  A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

  NCT05626114· Phase 2· Genentech, Inc.· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

  NCT06847854· Phase 1· Genentech, Inc.· Source

• Active, not recruiting

  Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

  NCT05296447· Phase 2· AbbVie· Source

• Active, not recruiting

  Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

  NCT05407636· Phase 3· AbbVie· Source

• Enrolling by invitation

  Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

  NCT05210803· Phase 2· AbbVie· Source

• Recruiting

  4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

  NCT05197270· Phase 1/2· 4D Molecular Therapeutics· Source

• Active, not recruiting

  Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

  NCT04704921· Phase 2/3· AbbVie· Source

• Active, not recruiting

  RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

  NCT04567550· Phase 2· AbbVie· Source

• Active, not recruiting

  RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT04514653· Phase 2· AbbVie· Source

• Active, not recruiting

  A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

  NCT04108156· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

  NCT03999801· Phase 2· AbbVie· Source

• Recruiting

  A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  NCT03178149· Phase 1· Astellas Institute for Regenerative Medicine· Source

• Active, not recruiting

  Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

  NCT02286089· Phase 1/2· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration12 recruiting
• Diabetic eye disease1 recruiting
• Retinitis pigmentosa1 recruiting

Closed trials

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· 4D Molecular Therapeutics· Source

• Completed

  A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

  NCT05839041· Phase 2· Aviceda Therapeutics, Inc.· Source

• Completed

  Vamikibart in Participants With Uveitic Macular Edema

  NCT05642325· Phase 3· Hoffmann-La Roche· Source

• Completed

  Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

  NCT05797896· Complement Therapeutics· Source

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Completed

  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

  NCT04770545· Phase 3· Apellis Pharmaceuticals, Inc.· Source

• Completed

  A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

  NCT04503551· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

  NCT04065490· LumiThera, Inc.· Source

• Completed

  A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

  NCT06771271· Phase 1· Hoffmann-La Roche· Source

• Terminated

  EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04437368· Phase 2· Gyroscope Therapeutics Limited· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Gyroscope Therapeutics Limited· Source

• Terminated

  FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

  NCT03846193· Phase 1/2· Gyroscope Therapeutics Limited· Source